Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. - Wikidata - wikimedia - TriplyDB

Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB.

Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB.

http://www.wikidata.org/entity/Q39900531

about

AT2 receptor activities and pathophysiological implications Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats A nonpeptide angiotensin II type 2 receptor agonist prevents renal inflammation in early diabetes.Angiotensin AT₂ receptor stimulation inhibits early renal inflammation in renovascular hypertension.Direct stimulation of angiotensin II type 2 receptor enhances spatial memory Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration.Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats.Classical Renin-Angiotensin system in kidney physiology Recent advances involving the renin-angiotensin system PPARγ signaling is required for mediating EETs protective effects in neonatal cardiomyocytes exposed to LPS Discovery of inhibitors of insulin-regulated aminopeptidase as cognitive enhancers.The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.Atherosclerotic renal artery stenosis: current status Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism.Angiotensin II, a Neuropeptide at the Frontier between Endocrinology and Neuroscience: Is There a Link between the Angiotensin II Type 2 Receptor and Alzheimer's Disease?The CD4(+) AT2R(+) T cell subpopulation improves post-infarction remodelling and restores cardiac function.Activation of angiotensin II type 2 receptor suppresses TNF-α-induced ICAM-1 via NF-кB: possible role of ACE2 Enalapril in Combination with Benznidazole Reduces Cardiac Inflammation and Creatine Kinases in Mice Chronically Infected with Trypanosoma cruzi.Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial Effects of combined radiation and burn injury on the renin-angiotensin system.Compound 21, a selective agonist of angiotensin AT2 receptors, prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo.Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial.Angiotensin AT2 receptor stimulation is anti-inflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production.Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats.AT(2) receptor and tissue injury: therapeutic implications.AT2 receptor non-peptide agonist C21 promotes natriuresis in obese Zucker rats.Angiotensin II type 2 receptor correlates with therapeutic effects of losartan in rats with adjuvant-induced arthritis.New insights into angiotensin receptor actions: from blood pressure to aging.Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage.Vascular smooth muscle cell motility: From migration to invasion.Angiotensin receptor modulation and cardiovascular remodeling.Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.Angiotensin II type 2 receptor agonists: where should they be applied?The regenerative potential of angiotensin AT2 receptor in cardiac repair.Key advances in antihypertensive treatment.Angiotensin II type 2 receptor agonists--where should they be applied?Impact of the AT(2) receptor agonist C21 on blood pressure and beyond.

P2860

Q26829592-326529CE-209F-40B7-A46F-F4577EF30B1E Q27009109-A660F778-7DEE-43D8-99A2-845777180FD4 Q28571720-EFFA9F51-88DC-4D39-B53E-7E39F83E1F7F Q30300953-AF87343D-54DF-4EA3-B6FA-3E05BD5D55E0 Q30432916-841AE07A-3968-4E9E-A7CA-457C1CEE7FB1 Q30504733-2A4E21B4-364E-4CA3-B854-842768B1C757 Q33166521-DE31D36C-19CA-45A9-8393-64771058E63A Q33627982-C9D255F3-DD51-480E-9895-182D1B03C128 Q34001678-D1F0E813-472E-44C5-A7BF-CD2B57D68DFC Q34065655-4361E851-FF75-4A41-9452-0B4A0B5D06C8 Q34260674-B743AD0D-BA59-4D31-8AC2-737F9FCE402F Q34488280-DA201732-941A-4376-87DC-4239CF9BDDFD Q34543485-5EC54266-66E5-494F-87C1-B94DC806620E Q35005356-B0FFCD3B-E094-4865-9304-BDE86195806F Q35484295-2E5EEB99-C44B-4ECC-9499-F772A3961E3D Q35537676-8DD99C7B-48DF-4196-AEBC-D8AB9D8913CA Q35849378-D5C92468-305B-4D36-9B40-539695794CA7 Q35971305-71695C81-9E1A-4F15-8C21-98E552425E13 Q35995120-F21BA97F-AE7A-46F4-88B0-4EB88BFFD911 Q36114299-7B34FB7C-8123-4C30-851F-73CB7732FC68 Q36436221-009B1623-75C8-4916-A0D3-3D61875E3DE7 Q36507890-E5B64E05-91DC-4E20-A1A2-2E03F7F93C28 Q36518078-1B66D248-F2B6-42C3-966D-0ABE9F2750CF Q36546985-F864D676-0D7D-425A-B909-3DE5C54206AE Q36716415-377089D6-5FD9-47EA-902E-A31DB0771765 Q36981859-C827D6DE-5313-4993-B345-5633F945C554 Q37007516-A50D750B-C1DE-4942-8290-B18D61016D05 Q37531017-01B2DA12-ACD6-4CCE-BC5C-BCAE5CF51847 Q37551661-6390E977-737D-44E8-83B4-F88B4F8F5298 Q37557554-2A459A71-090A-42A2-BD5E-FE48EA62ED00 Q37809435-E1DA32D4-4262-4F00-8CE8-08C33A8BCEFA Q37822830-BB534EAF-CD2E-4177-AF6C-92116D004C5F Q37832151-D2297EA4-4A61-47C6-BA5D-9CD9C5A3B7C6 Q37924418-0EE4254A-98E0-43C8-9A3C-4F21EB009E98 Q37939427-00783CA4-524D-465E-81BD-CFD1AD1CE239 Q37986143-3F1CDE7B-1A31-42B0-80CC-1A62A6D73345 Q37988002-2419460F-B91E-4384-8921-4520AFA3B81B Q37995074-E02FB0CD-C109-4F71-A2DF-27D79B8197E1 Q38004057-C41F9E11-2AC0-4C8A-93D9-801134720ED6 Q38029918-08A41BB3-61A5-4BDC-BBB4-45AA20EDE868

P2860

Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB.

http://www.wikidata.org/entity/Q39900531

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Direct angiotensin II type 2 r ...... tion of nuclear factor kappaB.

@en

Direct angiotensin II type 2 r ...... tion of nuclear factor kappaB.

@nl

type

label

Direct angiotensin II type 2 r ...... tion of nuclear factor kappaB.

@en

Direct angiotensin II type 2 r ...... tion of nuclear factor kappaB.

@nl

prefLabel

Direct angiotensin II type 2 r ...... tion of nuclear factor kappaB.

@en

Direct angiotensin II type 2 r ...... tion of nuclear factor kappaB.

@nl

P1433

Q39900531-79346061-D92C-4D71-8D45-DD6027996D77

P1476

Q39900531-7DDA41B0-AE75-45FB-9E70-6EBB0F7443E4

P2093

Q39900531-06EBEE8E-53BE-419D-B998-EEFE8E681D4B

Q39900531-20FDCC5F-E6B2-4AE8-8878-0B2B32459313

Q39900531-28F7AA4D-86FB-4115-8FBB-0615226917E4

Q39900531-37BD0052-533C-44B2-825D-0760F3091283

Q39900531-4B103341-C37C-4397-AC9A-3679F04836FE

Q39900531-69D6ABA5-E9D9-4957-BDD8-A36019570B16

Q39900531-715EAC63-6CD2-42E5-A21D-3A969C973AD1

Q39900531-73C4EF11-E3F5-4813-9162-83830FB39B0D

Q39900531-A3C70468-A847-45C7-A4DB-EC651B05B434

Q39900531-D10051FA-5FCE-4B35-9666-480EA8A3B12C

P304

Q39900531-74A13CED-0653-48F4-AE5E-3351F672F4E7

P31

Q39900531-5CAE1530-7D3E-4A7D-A85C-5F10ED374C3E

P356

Q39900531-57FA6B9F-4AE5-4E7C-9915-4E37CB67D89F

P407

Q39900531-E3E46697-CBF6-44F6-8667-4E70BD9503F5

P433

Q39900531-E892ED05-4595-4151-96C9-116DEDD22573

P478

Q39900531-4C4E164E-2E2F-4674-8070-1DB21E072893

P50

Q39900531-0E2BC275-748F-4435-BEBD-AE6FA614C18B

Q39900531-1904F23A-83C1-489B-8BF2-BD66E5BADB8A

Q39900531-800D06E5-6F00-4F3A-8937-8CD82F848821

Q39900531-A8C71B36-C6A6-4B4B-AF14-E62F77C2A740

Q39900531-C08008EF-77A4-490A-9F16-C84DAB577259

Q39900531-E54387E2-291B-405A-82F7-2C6E096E8428

Q39900531-F6C44579-3605-4A7D-A1F8-49C996AA5CF2

P577

Q39900531-E58276E5-D309-483D-A116-CB380C883BFF

P698

Q39900531-65137FBD-5FC5-4CCA-942E-B9C5B777BEA9

P921

Q39900531-5378D2D0-D0D4-4BBD-88E2-85F8CAC6CD5F

P356

HYPERTENSIONAHA.109.147843

P1433

P1476

Direct angiotensin II type 2 r ...... tion of nuclear factor kappaB.

@en

P2093

Anders Hallberg

http://www.w3.org/2001/XMLSchema#string

Anne Reichenbach

http://www.w3.org/2001/XMLSchema#string

Christa Thöne-Reineke

http://www.w3.org/2001/XMLSchema#string

Cosima Schmidt

http://www.w3.org/2001/XMLSchema#string

Franziska Rompe

http://www.w3.org/2001/XMLSchema#string

Jens Schacherl

http://www.w3.org/2001/XMLSchema#string

Katja Ströder

http://www.w3.org/2001/XMLSchema#string

Mathias Alterman

http://www.w3.org/2001/XMLSchema#string

Metin Artuc

http://www.w3.org/2001/XMLSchema#string

Natalia Alenina

http://www.w3.org/2001/XMLSchema#string

P304

924-931

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/HYPERTENSIONAHA.109.147843

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Torsten Zuberbier

Markus Schwaninger

Ulrike Steckelings

Heiko Funke-Kaiser

P577

2010-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20157051

http://www.w3.org/2001/XMLSchema#string

P921